We are committed to expanding our pipeline with high-quality assets that complement our flagship EFX asset. Compelling science governs our evaluations, with an emphasis on assets that complement EFX’s therapeutic profile as a potential therapy for MASH. We also continually evaluate the potential for EFX to be developed for patients with other serious metabolic diseases.